Changying Jiang

2.5k total citations
59 papers, 1.3k citations indexed

About

Changying Jiang is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Changying Jiang has authored 59 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Changying Jiang's work include Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (15 papers) and CAR-T cell therapy research (12 papers). Changying Jiang is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (15 papers) and CAR-T cell therapy research (12 papers). Changying Jiang collaborates with scholars based in United States, China and Canada. Changying Jiang's co-authors include Xin Lin, Xueqiang Zhao, Yun You, Nilabh Shastri, Shelley R. Starck, Tingting Wang, Tao Pan, Mariana Pavon-Eternod, Deng Pan and Brian P. McCarthy and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Changying Jiang

52 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Changying Jiang United States 20 640 360 265 233 180 59 1.3k
Barbara Boone Belgium 15 582 0.9× 423 1.2× 401 1.5× 223 1.0× 84 0.5× 24 1.6k
Shie-Liang Hsieh Taiwan 20 742 1.2× 676 1.9× 177 0.7× 160 0.7× 155 0.9× 44 1.5k
Farhad Seif Iran 18 533 0.8× 406 1.1× 282 1.1× 131 0.6× 297 1.6× 76 1.7k
Alma Chávez‐Blanco Mexico 24 1.2k 1.9× 271 0.8× 344 1.3× 210 0.9× 331 1.8× 70 2.0k
Kezhen Li China 22 636 1.0× 266 0.7× 336 1.3× 162 0.7× 228 1.3× 61 1.5k
Jeffrey J. Bednarski United States 21 906 1.4× 440 1.2× 264 1.0× 183 0.8× 128 0.7× 53 1.6k
Hongmin Chen United States 19 786 1.2× 398 1.1× 282 1.1× 170 0.7× 160 0.9× 33 1.6k
Katrin Peter Germany 21 1.0k 1.6× 645 1.8× 447 1.7× 202 0.9× 361 2.0× 39 1.9k

Countries citing papers authored by Changying Jiang

Since Specialization
Citations

This map shows the geographic impact of Changying Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changying Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changying Jiang more than expected).

Fields of papers citing papers by Changying Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changying Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changying Jiang. The network helps show where Changying Jiang may publish in the future.

Co-authorship network of co-authors of Changying Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Changying Jiang. A scholar is included among the top collaborators of Changying Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changying Jiang. Changying Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Changying, Qingsong Cai, Yang Liu, et al.. (2025). YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma. Blood Advances. 9(19). 4963–4976.
2.
Li, Yijing, Changying Jiang, Fangfang Yan, et al.. (2025). BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma. Cancer Letters. 632. 217961–217961.
3.
Zhang, Xian, et al.. (2024). A Delphi Study to Construct an Index of Practice for Community Nurses Providing Transitional Home Care for Patients with Chronic Diseases. INQUIRY The Journal of Health Care Organization Provision and Financing. 61. 2876840202–2876840202. 1 indexed citations
4.
Jiang, Changying, Omar Alhalabi, Amanda Nizam, et al.. (2024). 8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO Open. 9. 102263–102263. 1 indexed citations
5.
Lee, William, Changying Jiang, Fangfang Yan, et al.. (2023). The Selective CDK9 Inhibitor VIP152 Overcame Therapeutic Resistance in Mantle Cell Lymphoma. Blood. 142(Supplement 1). 2821–2821. 3 indexed citations
6.
Che, Yuxuan, Yang Liu, Yijing Li, et al.. (2023). Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma. Blood Advances. 7(14). 3361–3365. 1 indexed citations
7.
Li, Yijing, Heng‐Huan Lee, Changying Jiang, et al.. (2023). Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death and Disease. 14(11). 714–714. 5 indexed citations
8.
Jiang, Changying, et al.. (2020). Xanthohumol Inhibits TGF-β1-Induced Cardiac Fibroblasts Activation via Mediating PTEN/Akt/mTOR Signaling Pathway. SHILAP Revista de lepidopterología. 1 indexed citations
9.
Tong, Sebastian T., Camille J. Hochheimer, Roy Sabo, et al.. (2019). Chronic Opioid Prescribing in Primary Care: Factors and Perspectives. The Annals of Family Medicine. 17(3). 200–206. 43 indexed citations
10.
Guo, Hui, Dongfeng Zeng, Hui Zhang, et al.. (2018). Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 38(11). 1802–1814. 20 indexed citations
11.
Zheng, Guoxing, Changying Jiang, Yulin Li, et al.. (2018). TMEM43-S358L mutation enhances NF-κB-TGFβ signal cascade in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Protein & Cell. 10(2). 104–119. 33 indexed citations
12.
Liu, Yang, Yanzhen Yin, Hui Zhang, et al.. (2017). Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. European Journal of Medicinal Chemistry. 138. 543–551. 19 indexed citations
13.
Pan, Deng, Yifan Zhu, Zhicheng Zhou, et al.. (2015). The CBM Complex Underwrites NF-κB Activation to Promote HER2-Associated Tumor Malignancy. Molecular Cancer Research. 14(1). 93–102. 32 indexed citations
14.
Pan, Deng, Changying Jiang, Zhongliang Ma, et al.. (2015). MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression. Oncogene. 35(7). 919–928. 48 indexed citations
15.
Starck, Shelley R., Changying Jiang, Mariana Pavon-Eternod, et al.. (2012). Leucine-tRNA Initiates at CUG Start Codons for Protein Synthesis and Presentation by MHC Class I. Science. 336(6089). 1719–1723. 171 indexed citations
16.
Jiang, Changying & Xin Lin. (2012). Regulation of NF‐κB by the CARD proteins. Immunological Reviews. 246(1). 141–153. 77 indexed citations
17.
Heckman‐Stoddard, Brandy M., Tracy Vargo-Gogola, Changying Jiang, et al.. (2009). Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Research. 11(4). R61–R61. 24 indexed citations
18.
Starck, Shelley R., Changying Jiang, Maria Tokuyama, et al.. (2008). A Distinct Translation Initiation Mechanism Generates Cryptic Peptides for Immune Surveillance. PLoS ONE. 3(10). e3460–e3460. 37 indexed citations
19.
Jiang, Changying, et al.. (2006). Herpes simplex virus type 1 recombinants without the ori sequence replicate DNA with increased fidelity. Virology. 347(2). 277–285. 4 indexed citations
20.
Luo, Xiuquan, et al.. (2005). Genotoxic and endoplasmic reticulum stresses differentially regulate TRB3 expression. Cancer Biology & Therapy. 4(10). 1063–1067. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Boone Breakdown of academic impact, for papers by Shie-Liang Hsieh Breakdown of academic impact, for papers by Farhad Seif Breakdown of academic impact, for papers by Alma Chávez‐Blanco Breakdown of academic impact, for papers by Kezhen Li Breakdown of academic impact, for papers by Jeffrey J. Bednarski Breakdown of academic impact, for papers by Hongmin Chen Breakdown of academic impact, for papers by Katrin Peter
Rankless by CCL
2026